Can-Fite BioPharma (CANF) Return on Assets (2014 - 2025)
Can-Fite BioPharma's (CANF) quarterly Return on Assets came in at 0.03% in Q2 2025, up 1.0% YoY from 0.03% in Q2 2024, and up 16.16% on a QoQ basis from 0.04% in Q4 2024.
Can-Fite BioPharma (CANF) Return on Assets (2014 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 12 years of Return on Assets data on file, last reported at 0.03% in Q2 2025.
- Quarterly Return on Assets rose 1.0% year-over-year to 0.03% in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 0.03% (up 1.0% YoY) and the FY2025 annual result came in at 0.01%, changed 0.0% from the prior year.
- Return on Assets rose to 0.03% in Q2 2025, from 0.04% in the prior quarter.
- In the past five years, Return on Assets ranged from a high of 0.01% in Q1 2022 to a low of 0.04% in Q2 2024.
- A 5-year average of 0.02% and a median of 0.03% in 2023 frame the typical range for Return on Assets.
- Annual changes were most pronounced in 2022 — Return on Assets fell 2 bps — and 2025, when it gained 1 bps.
- Tracing CANF's Return on Assets over 5 years: stood at 0.01% in 2021, then tumbled by 257 bps to 0.03% in 2022, then retreated by 18 bps to 0.04% in 2023, then retreated by 8 bps to 0.04% in 2024, then gained by 16 bps to 0.03% in 2025.
- The last three Return on Assets figures came in at 0.03% (Q2 2025), 0.04% (Q4 2024), and 0.04% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 0.00% |
| 10 | Can-Fite BioPharma | 2.77 Mn | -8.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -0.03% |
| Dec 31, 2024 | -0.04% |
| Jun 30, 2024 | -0.04% |
| Dec 31, 2023 | -0.04% |
| Sep 30, 2023 | -0.03% |
| Jun 30, 2023 | -0.03% |
| Mar 31, 2023 | -0.03% |
| Dec 31, 2022 | -0.03% |
| Sep 30, 2022 | -0.01% |
| Jun 30, 2022 | -0.01% |
| Mar 31, 2022 | -0.01% |
| Dec 31, 2021 | -0.01% |
| Sep 30, 2021 | -0.01% |
| Jun 30, 2021 | -0.01% |
| Mar 31, 2021 | -0.01% |
| Dec 31, 2020 | -0.01% |
| Sep 30, 2020 | -0.01% |
| Dec 31, 2019 | -0.01% |
| Sep 30, 2019 | -0.01% |
| Jun 30, 2019 | -0.01% |